DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma
Authors:
Open Access
- 6 April 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 13 (6) , 4109-4116
Abstract
The present study was designed to determine the significance of DNA topoisomerase IIa (TopoIIα) and Ki67 in hepatocellular carcinoma cells (HCCs). The present study included 353 patients with HCC. The association of clinicopathological data with the expression of TopoIIα and Ki67 by immunohistochemistry was analyzed by χ2 test. Cox multivariate proportional hazards regression analysis and Kaplan‑Meier analysis were performed with all the variables to derive risk estimates associated with overall survival (OS)/recurrence‑free survival (RFS) and to control for confounders. TopoIIα and Ki67 were detected in the nuclei of the tumor cells. With TopoIIα, 35.7% of cells exhibited high expression, which was associated with tumor‑node‑metastasis stage, tumor size and α‑fetoprotein level. With Ki67, 37.1% of cells exhibited high expression, which was associated with tumor‑node‑metastasis stage, tumor size and α-fetoprotein level. Correlation was identified between the expression level of TopoIIα and Ki67 in HCCs (r=0.444). Multivariate analysis revealed that high TopoIIα expression is a prognostic indicator for RFS [hazard ratio (HR), 2.002; 95% confidence interval (CI), 1.429‑2.806] and OS (HR, 2.749; 95% CI, 1.919‑3.939), and high Ki67 expression is a prognostic indicator for OS (HR, 1.816; 95% CI, 1.273‑2.589). The TopoIIα‑low group had a significantly increased RFS rate (55.6 vs. 31.7%) and OS rate (66.5 vs. 23.8%) compared with the TopoIIα‑high group. The OS rate was increased in the Ki67‑low group compared with the Ki67‑high group (67.0 vs. 26.5%). Expression of TopoIIα and Ki67 are independent prognostic factors for survival in HCCs. TopoIIα was positively associated with Ki67 expression.Keywords
This publication has 36 references indexed in Scilit:
- Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: A historical prospective studyDiagnostic Pathology, 2011
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapiesTherapeutic Advances in Gastroenterology, 2009
- Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosisCancer Letters, 2009
- Expression of Human DNA Topoisomerase II-α in Squamous Cell Carcinoma of the Larynx and Its Correlation With Clinicopathologic VariablesAmerican Journal of Clinical Pathology, 2008
- DNA topoisomerase II, genotoxicity, and cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Association Between p53 Expression and Bcl-2, P-glycoprotein, Topoisomerase II Alpha, Thymidylate Synthase and Thymidine Phosphorylase as Potential Therapeutic Targets in Colorectal Cancer PatientsPakistan Journal of Biological Sciences, 2007
- Origin and evolution of DNA topoisomerasesBiochimie, 2007
- Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literatureJournal of Cancer Research and Clinical Oncology, 2004
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000